If you have spent any time researching medical weight loss, you have probably run into this question. And you have probably found a dozen articles that each give a slightly different answer, usually leaning toward whichever medication the writer’s platform happens to sell.
Here is the honest answer up front: there is no single “best” GLP-1 for weight loss. The medication that works best is the one that fits your individual health profile, your tolerance for side effects, your budget, and your long-term goals. That is not a cop-out answer. It is the clinically accurate one.
What we can do is look at the evidence for the major GLP-1 options, compare what the trials actually show, and help you understand the factors that matter when making this decision with your provider.
Individual results vary. Drug selection should be based on a thorough medical evaluation with a licensed provider.
The GLP-1 Medications Currently Available
Three medications dominate the conversation around GLP-1 therapy for weight loss. Understanding what each one is and how it works will help frame the comparison.
Semaglutide is a GLP-1 receptor agonist, meaning it targets a single receptor system. It is the active ingredient in Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management). Semaglutide is also available in compounded formulations through licensed pharmacies. It is administered as a once-weekly subcutaneous injection.
Tirzepatide is a dual GLP-1/GIP receptor agonist. It targets both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, which is why you will sometimes hear it described as a “dual agonist” or “twincretin.” Tirzepatide is the active ingredient in Mounjaro (for diabetes) and Zepbound (for weight management). It is also available as a compounded medication through qualified pharmacies. Like semaglutide, it is a weekly injection.
Liraglutide (brand name Saxenda) is an older GLP-1 receptor agonist that requires daily injections. While it was the first GLP-1 approved specifically for weight management, its clinical outcomes are more modest compared to semaglutide and tirzepatide. For that reason, liraglutide is prescribed less frequently for weight loss today, though it remains an option in specific clinical situations.
What the Clinical Trial Data Shows
Clinical trials give us the most objective comparison we have, though it is important to understand their limitations. Most of the major trials compared each drug against placebo, not directly against each other, which makes head-to-head conclusions tricky.
The STEP trial program evaluated semaglutide 2.4 mg for weight management. In the landmark STEP 1 trial published in the New England Journal of Medicine, participants without diabetes lost an average of approximately 15% of their body weight over 68 weeks. Around 86% of participants achieved at least 5% weight loss, and about a third lost 20% or more. Those numbers were considered remarkable at the time of publication.
The SURMOUNT trial program evaluated tirzepatide. In the SURMOUNT-1 trial, also published in the NEJM, the results were even more striking. Participants on the highest dose (15 mg) lost an average of 22.5% of their body weight over 72 weeks. Roughly 96% of participants on the 10 mg and 15 mg doses achieved at least 5% weight loss, and more than half on the highest dose lost over 20%.
On raw percentage weight loss, tirzepatide appears to have an edge. But there are a few things to consider before concluding that it is automatically “better.”
Why the Numbers Do Not Tell the Whole Story
Trial populations were not identical. The STEP and SURMOUNT participants had somewhat different demographic profiles, baseline BMIs, and comorbidity distributions. Comparing average outcomes across different trial populations is informative but not the same as a controlled head-to-head study.
Side effect profiles differ. Both medications cause gastrointestinal side effects, but the patterns are not identical. Some patients tolerate semaglutide well but struggle with tirzepatide, and the reverse is also true. Nausea, constipation, and diarrhea are common with both, particularly during dose escalation. Your personal tolerance can make or break your experience with either medication.
Cost and access vary. Brand-name tirzepatide and semaglutide have different pricing structures, insurance coverage patterns, and availability through compounding pharmacies. For some patients, the “best” medication is the one they can actually afford and access consistently.
Individual metabolic response is unpredictable. Some patients respond dramatically to semaglutide and see only modest additional benefit from tirzepatide. Others plateau on semaglutide and do significantly better after switching. There is currently no reliable way to predict which patient will respond best to which drug before trying it.
Factors That Actually Guide the Decision
When a provider is helping a patient choose between GLP-1 options, they consider a combination of clinical and practical factors. Here are the ones that matter most.
Health history and comorbidities play a role. Both medications carry an FDA boxed warning regarding thyroid C-cell tumors (based on rodent data), and both are contraindicated in patients with a history of medullary thyroid carcinoma or MEN2.
Beyond that, factors like existing diabetes, cardiovascular risk, kidney function, and history of pancreatitis can all influence which drug is a better fit. You can review the full scope of prescribing and safety considerations to understand what providers evaluate.
Side effect tolerance is practical and personal. If a patient has had significant GI issues on one medication, switching to the other is a reasonable clinical move. Some patients find that tirzepatide’s dual mechanism produces a different side effect experience than semaglutide’s GLP-1 monoagonism.
Cost and insurance coverage often end up being the deciding factor for many patients. Brand-name Wegovy and Zepbound are expensive, and insurance coverage is inconsistent. Compounded options through programs like those offered by Precision Telemed can make both medications significantly more accessible, but patients should understand what they are getting and from where.
Patient preference and lifestyle fit matter too. Some patients prefer the idea of a dual-agonist mechanism. Others want to start with the medication that has the longer track record (semaglutide has been on the market longer than tirzepatide for weight management). Neither preference is wrong.
What About Maintenance and Long-Term Use?
Weight loss medications are not short-term interventions. The clinical data consistently shows that weight tends to return when treatment is discontinued. This means the choice of medication is also a question about long-term tolerability and sustainability.
For patients who have reached their goal weight and want to transition to a lower maintenance dose, both semaglutide and tirzepatide offer options. Some providers use microdose GLP-1 protocols for long-term maintenance, keeping patients on a lower dose to sustain results without the full side effect burden of a therapeutic dose.
The “best” GLP-1 for maintenance may not be the same as the best one for initial weight loss. Some patients achieve their target on tirzepatide and then transition to semaglutide for maintenance. Others stay on the same medication at a reduced dose. This is another decision that benefits from ongoing provider guidance.
So, Which One Should You Choose?
If you were hoping for a definitive answer, I understand the frustration. But the truth is that drug selection should be based on a thorough medical evaluation, not on an internet article telling you which one “wins.”
Both semaglutide and tirzepatide are highly effective GLP-1 medications with strong clinical data behind them. The one that is best for you depends on your health history, your goals, your tolerance, and your circumstances.
The most productive next step is to have that conversation with a provider who can review your complete picture. A telehealth consultation is built for exactly this kind of decision. Your provider can walk through both options with you, explain how each one might work for your specific situation, and help you make an informed choice based on real clinical criteria, not marketing.
Individual results vary. Drug selection should be based on a thorough medical evaluation with a licensed provider.